NCT07081022

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 180 (estimated)
• Sponsor: Shanghai Junshi Bioscience Co., Ltd. · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma

Conditions

• B-cell Non-Hodgkin's Lymphoma

Interventions

Type	Name	Description
DRUG	JS203 in combination with gemcitabine and oxaliplatin	Gemcitabine and oxaliplatin 8 cycles (Q3W) and JS203 (21 days/cycle) Cycle 1 QW,Cycle 2 and therafter Q3W until progression or unacceptable toxicity.
DRUG	JS203 in combination with ifosfamide, carboplatin and etoposide	Ifosfamide, carboplatin and etoposide, 3 cycles (Q3W) and JS203, Cycle 1 QW, Cycle 2 and therafter Q3W until trasnplant, progression or unacceptable toxicity.
DRUG	JS203 in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone	Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone 6 cycles (Q3W) and JS203, 8 cycles (21 days/cycle), Cycle 1 QW, Cycle 2 to Cycle 8 Q3W.
DRUG	JS203 combined with lenalidomide	lenalidomide,12 cycles, Cycle 1(Q3W), Cycle 2 to Cycle 12 (Q4W) and JS203, 12 cycles, Cycle 1 (21 days/cycle) QW, Cycle 2 to Cycle 12 (28 days/cycle) Q4W.

Timeline

• Start date: 2025-08-17
• Primary completion: 2027-04-06
• Completion: 2027-04-06
• First posted: 2025-07-23
• Last updated: 2025-08-21

Locations

1 site across 1 country: China